Research location
Ft. Pierce
Florida, United States
Advertisement
Research activity in Ft. Pierce
Florida, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 105 trials and 106 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ft. Pierce
105 linked trials · page 1 of 3Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyNCT07682961 · 2026-07-14 · 1 site observation
RECRUITING
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedNCT07650916 · 2026-06-25 · 1 site observation
RECRUITING
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidENCT07476339 · 2026-06-17 · 1 site observation
RECRUITING
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)NCT07202546 · 2026-02-11 · 1 site observation
RECRUITING
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)NCT07266831 · 2025-12-18 · 1 site observation
RECRUITING
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies StudyNCT07215468 · 2025-12-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)NCT07047716 · 2025-07-22 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVNCT07053384 · 2025-07-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)NCT06741397 · 2024-12-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382NCT06032546 · 2023-10-12 · 1 site observation
TERMINATED
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)NCT05996471 · 2023-08-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAFNCT05911360 · 2023-07-07 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05917509 · 2023-07-06 · 1 site observation
COMPLETED
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)NCT05766501 · 2023-03-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)NCT05631093 · 2023-02-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)NCT05630755 · 2023-02-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)NCT05393037 · 2022-07-13 · 1 site observation
COMPLETED
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected ParticipantsNCT05896761 · 2021-10-28 · 1 site observation
COMPLETED
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVNCT05052996 · 2021-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive AdultsNCT04900038 · 2021-08-18 · 1 site observation
TERMINATED
Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionNCT04925752 · 2021-06-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)NCT04554966 · 2021-04-16 · 1 site observation
COMPLETED
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)NCT04652700 · 2021-03-15 · 1 site observation
TERMINATED
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]NCT04564547 · 2021-03-09 · 1 site observation
COMPLETED
A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive AdultsNCT04493216 · 2020-11-18 · 1 site observation
TERMINATED
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically SuppressedNCT04542070 · 2020-11-09 · 1 site observation
COMPLETED
Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart FailureNCT04452149 · 2020-09-03 · 1 site observation
COMPLETED
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight GainNCT04442737 · 2020-07-01 · 1 site observation
COMPLETED
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)NCT04233879 · 2020-02-28 · 1 site observation
COMPLETED
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)NCT04223791 · 2020-02-18 · 1 site observation
COMPLETED
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)NCT04223778 · 2020-02-18 · 1 site observation
COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1NCT04223804 · 2020-01-30 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVNCT04143594 · 2019-11-22 · 1 site observation
COMPLETED
Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected AdultsNCT03945981 · 2019-07-02 · 1 site observation
COMPLETED
Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third TrimestersNCT03960645 · 2019-06-28 · 1 site observation
COMPLETED
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected AdultsNCT03739866 · 2018-11-26 · 1 site observation
COMPLETED
Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE StudyNCT03639311 · 2018-09-24 · 1 site observation
COMPLETED
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)NCT03446573 · 2018-01-18 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsNCT03299049 · 2017-10-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of CareNCT03227861 · 2017-07-31 · 1 site observation
COMPLETED
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedNCT03110380 · 2017-06-12 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected ControllersNCT03060447 · 2017-05-09 · 1 site observation
COMPLETED
Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected AdultsNCT03045861 · 2017-03-17 · 1 site observation
COMPLETED
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionNCT02859961 · 2016-12-07 · 1 site observation
COMPLETED
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsNCT02951052 · 2016-10-28 · 1 site observation
ACTIVE_NOT_RECRUITING
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)NCT02831673 · 2016-07-21 · 1 site observation
COMPLETED
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)NCT02831764 · 2016-07-18 · 1 site observation
COMPLETED
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart FailureNCT02698241 · 2016-05-01 · 1 site observation
TERMINATED
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentNCT02707601 · 2016-04-01 · 1 site observation
COMPLETED
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsNCT02605954 · 2015-11-18 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.